olaptesed pegol
Trade name: Spiegelmer
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT00976378)
Timeline
Indications
Mechanism of action
- Stromal cell-derived factor 1INHIBITOR
CXCL12 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594485 ↗
Also known as
- nox-a12
- olaptesed pegol
- olaptesed pegol
- olaptesed pegol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04901741 | Phase 2 | Oct 31, 2021 | Merck, Noxxon AG |
| NCT04121455 | Phase 1/Phase 2 (Phase 2) | Sep 12, 2019 | Noxxon AG |
| NCT03168139 | Phase 1/Phase 2 (Phase 2) | Apr 18, 2017 | Merck, Noxxon AG |
| NCT01521533 | Phase 2 | Mar 1, 2012 | Noxxon AG |
| NCT01486797 | Phase 2 | Mar 1, 2012 | Noxxon AG |
| NCT01194934 | Phase 1 | Aug 1, 2010 | Noxxon AG |
| NCT00976378 | Phase 1 | Oct 1, 2009 | German Federal Ministry of Education and Research, Noxxon AG |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Noxxon AG | For profit | 7 | 7 | 2 | 2009 |
| Merck | For profit | 2 | 0 | 1 | 2017 |
| German Federal Ministry of Education and Research | Government | 1 | 0 | 1 | 2009 |
3 organizations
Page 1 / 1